Recombinant CDK8 Monoclonal Antibody (AN301488L)
For research use only.
| Verified Samples |
Verified Samples in WB: HeLa, K562, HCT-116 Verified Samples in IHC: Human breast cancer, Mouse colon |
| Dilution | WB 1:500-1:1000, IHC 1:50-1:100 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, Mouse |
| Applications | WB, IHC |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant human CDk8 fragment |
| Abbre | CDK8 |
| Synonyms | CDK, CDK8, K35, Cell division protein kinase 8 |
| Swissprot | |
| Calculated MW | 53 kDa |
| Observed MW |
53 kDa
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Nucleus |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Cell Biology, Epigenetics and Nuclear Signaling |
| Clone No. | A183 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Cyclin-dependent kinase 8 (CDK8) is a cell cycle regulator, which can activate cyclin C, act in the G1/S phase, and regulate the normal cell cycle. CDK8 together with Cyclin, Med12 and Med13 form an intermediary complex, which is widely involved in the transmission of information between RNA polymerase II and gene-specific transcription factors, which can activate and inhibit transcription. In addition, CDK8 can activate a variety of signal transduction pathways such as Wnt/β-catenin and Notch, thereby inducing the occurrence and metastasis of malignant tumors such as rectal cancer and melanoma. Recent studies have found that blocking the activity of CDK8 gene can greatly reduce the glucose utilization rate of cancer cells. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
